Trikafta Access Update – 20 Aug 21

Trikafta has been recommended for reimbursement for people 12+ years with one F508del gene mutation and one minimal function mutation. This is great news for 390+ Australians who have not had access to a CFTR modulator prior to Trikafta. We eagerly await advice on the details of the roll-out.

However, Trikafta was not recommended for reimbursement for people F508del homozygous and F508del heterozygous with a Residual or Gating mutation. The push for this access will continue.

Although this is not the news we had hoped for, we are pleased that this is a step in the right direction.